1. Flow Cytometry 2012: Market Needs, Emerging Developments
and Future Use
Report Details:
Published:September 2012
No. of Pages:
Price: Single User License – US$2355
Biopharm Reports has carried out a study of market needs in the flow cytometry field. This study
examined current techniques and applications, end-users’ plans for using flow cytometry over the
next three years, as well as preferred products, purchasing and new developments. The findings
of this study provide valuable support to developers and vendors operating in this field.
This study involved the participation of 260 experienced flow cytometry users and decision-makers
in 53 countries. It investigated current and future applications, current and future purchasing plans,
research vs. clinical use across the study, new and emerging applications, end-users’ principal
flow cytometers and their strengths and weaknesses, current annual and future budgets, budget
breakdown, main consumables, challenges, innovation, use of analysis (offline) software, quality
control guidelines, sample preparation, and other areas. As part of this study, end-users provided
details of their anticipated purchases from suppliers in this field, over the period 2012 – 2015.
Key Findings
•Routine use: Use of flow cytometry (FC) by end-users for routine (developed and validated) FC
tests, the development or validation of FC tests and for qualitative discovery using FC methods.
•Companies: End-users' purchases/use of FC systems from more than 25 companies and their
anticipated use of these systems over the next three years, each ranked according to their
competitive position
•General and clinical: FC use (defined in this study description) by research scientists/research
managers and clinicians/physicians
•FC methods: Current use of more than 25 FC general applications and 15 clinical applications by
end-users and the anticipated use of these applications over the next three years, each ranked
according to their competitive position.
•Main applications: End-users’ two main applications of FC, each ranked according to their
competitive position.
•New applications: New FC applications used by end-users in the last three years, each ranked
according to their competitive position.
•Emerging applications: Emerging applications of FC, indicated by end-users.
•Main flow cytometer: End-users’ main flow cytometer, each ranked according to their competitive
position.

2. •Strengths: End-users’ disclosures of the strengths of their main flow cytometer, each ranked
according to their competitive position.
•Weaknesses: End-users’ disclosures of the weaknesses of their main flow cytometer, each
ranked according to their competitive position.
•Current financial budgets: End-users’ annual financial budgets for FC studies.
•Current budget breakdown: The breakdown of end-users’ FC financial budgets in nine key areas,
relating to their current expenditure on FC products and activities.
•Future financial budgets: End-users’ anticipated financial budget changes (percentage increases
or decrease, a measure of the financial growth of this field) over the next three years, relating to
their FC activities.
•Consumables: End-users’ top consumables, associated with their FC activities.
•Quality control guidelines: End-users’ adherence to quality control guidelines or procedures,
relating to the conduct of FC studies.
•Cost per sample: End-users’ disclosures on the costs per sample analysed, using FC.
•Current challenges: End-users’ disclosures on the parameters or measurements that present the
greatest technical challenges to FC analysis, together with the associated sample types
(matrices), associated FC methods and underlying reasons.
•Innovation: End-users’ disclosures relating to 11 key areas of required innovation in the FC field,
each ranked (on a scale of 1 to 10) according to their importance.
•Biomarkers: End-users’ application of FC methods for the study of disease biomarkers, namely
molecular types and their clinical utilities.
•Organisations: End-users organisations include clinics or hospitals, government bodies, large
international companies, research institutes, small and medium sized companies, universities and
veterinary centres.
•Fields: End-users professional fields include biotechnology, chemicals, clinical or hospital,
defence, energy, environmental, food and drink, forensics, geology, government, healthcare,
natural products, pharmaceuticals, research institutes, security and universities.
•Therapeutic areas: End-users’ FC activities in terms of their general therapeutic area (20 different
areas covered), including the main diseases to which their work in this field relates.
•Software: End-users’ disclosures on their preferred analysis (off-line) software, associated with
FC studies.
•Purpose: End-users’ underlying reasons for using FC analysis across 17 major fields
(biotechnology, chemicals, clinical or hospital, defence, diagnostics (medical), energy,
environmental, food and drink, forensics, geology, government, healthcare, natural products,
pharmaceuticals, research institutes, security, university), each ranked according to their relative
importance.
•Study samples: Study sample types analysed by end-users using FC methods, each ranked
according to their relative importance.
•Sample preparation: The use of sample preparation methods by end-users for FC studies, each
ranked according to their importance.

3. Get your copy of this report @
http://www.reportsnreports.com/reports/191887-flow-cytometry-2012-market-needs-emerging-developments-and-
future-use.html
Major points covered in Table of Contents of this report include
Table of Contents
1 Introduction
2 Study Participants
Investigated: Participants’ countries, regions, organisation types, departments and professional
fields. Figures and/or tables are also presented.
2.1 This chapter
2.2 Countries
2.3 Regions
2.4 Organisation types
2.5 Departments
2.6 Fields
2.7 Discussion
Fields:
Biotechnology
Chemicals
Clinical or Hospital
Defense
Diagnostics (Medical)
Energy
Environmental
Food and Drink
Forensics
Geology
Government
Healthcare
Natural Products
Pharmaceuticals
Research Institute
Security
University
Other
Organisation Types
University
Research Institute
Small or Medium Sized Company
Large International Company
Clinic or Hospital
Government Organisation

4. Veterinary Organisation
Other
3 Purpose of Flow Cytometry
Investigated: Participants’ purpose or reasons for using flow cytometry in their specified fields (see
Fields, Chapter 2). The purposes or reasons for using flow cytometry, which may be unique to
particular fields, were taken into account. Example: The purpose or reasons for using flow
cytometry in the “Clinical or Hospital” field were clinical research, routine diagnostics, routine
screening, clinical trials, treatment monitoring, diagnostics research, disease research, drug R&D,
drug targets, pathology, toxicology and other. Figures and/or tables are also presented.
3.1 This chapter
3.2 Purpose
3.3 Discussion
4 Main Activities
Investigated: The professional roles of study participants, namely as researchers or research
managers, clinicians or physicians. Figures and/or tables are also presented.
4.1 This chapter
4.2 Researchers or Research Managers
4.3 Clinicians or Physicians
4.4 Discussion
5 Flow Cytometric Tests
Investigated: Participants’ use of flow cytometry in one of three areas, namely i) the running of
routine cytometric tests ii) the developing of new cytometric tests or iii) qualitative (cytometric)
discovery. Figures and/or tables are also presented.
5.1 This chapter
5.2 Flow cytometric tests
5.3 Discussion
6 Therapeutic Area
Investigated: The therapeutic area(s) in which study participants work, relating to their use of flow
cytometry. Figures and/or tables are also presented.
6.1 This chapter
6.2 Therapeutic Areas
6.3 Discussion
Therapeutic Areas
Arthritis
Autoimmune Diseases
Bone Metabolism
Cancer
Cardiovascular
Central Nervous System
Dentistry
Dermatology
Endocrine

5. Gastrointestinal
Genito-urinary System
Haematology
Infections
Inflammation
Metabolic Disorders
Musculoskeletal Disorders
Nutrition
Obstetrics and Gynaecology
Ophthalmology
Pain
Psychiatry
Respiratory
Skin
Other
7 Main Diseases
Investigated: The main disease areas in which study participants work, relating to their use of flow
cytometry. Figures and/or tables are also presented.
7.1 This chapter
7.2 Disease areas
7.3 Discussion
8 Samples
Investigated: The sample types analysed by study participants, using flow cytometry. Figures
and/or tables are also presented.
8.1 This chapter
8.2 Samples
8.3 Discussion
Sample Types
Animal tissues
Cerebrospinal fluid
Bone Marrow
Human tissues
Microbiological materials
Pathology samples
Plant materials
Lymph
Saliva
Urine
Whole blood
Other
9 General Applications
Investigated: Participants current and anticipated future use (2012 – 2015) of flow cytometry, in

6. respect of 26 specified general applications, or others. Figures and/or tables are also presented.
9.1 This chapter
9.2 Current general applications
9.3 Anticipated future general applications
9.4 Discussion
General Application Areas
ADME Studies
Toxicity studies
Apoptosis
Bacteria analysis
Bacterial membrane potential
Bead-based immunoassays
Cell adherence
Cell cycle
Cell signalling
Cell sorting
Cellular kinetics
DNA and RNA content
Protein expression
FRET
Immunophenotyping
Intracellular calcium flux
Membrane asymmetry
Mitochondrial membrane potential
Multicolour Flow Cytometry
Necrosis
Organelle function
Protein expression and localization
Rare event analysis
Stem cell research
T Cell immunology
Transgenic products (e.g. GFP)
Other
10 Clinical Applications
Investigated: Participants current and anticipated future use (2012 – 2015) of flow cytometry, in
respect of 19 specified clinical applications, or others. Figures and/or tables are also presented.
10.1 This chapter
10.2 Current clinical applications
10.3 Anticipated future clinical applications
10.4 Discussion
Clinical Applications
Cell counting

7. Cell function
Cell pigments
Cell Proliferation
Cell surface antigens (e.g. CD markers)
Cell viability
Diagnosis of haematologic malignancies
DNA ploidy
Enzymatic activity
Infectious diseases
Intracellular antigens
Minimal residual disease
Monitoring AIDS patients
Monitoring chemotherapy
Multidrug Resistance (MDR)
Organ or stem-cell transplantation
Platelet function analysis
Transfusion medicine
Volume and morphology of cells
Other
11 Main Applications
Investigated: Participants main flow cytometry applications. Figures and/or tables are also
presented.
11.1 This chapter
11.2 Main applications
11.3 Discussion
12 New Applications
Investigated: New flow cytometry applications that study participants anticipate they will be using
in the next three years. Figures and/or tables are also presented.
12.1 This chapter
12.2 New applications
12.3 Discussion
13 Emerging Applications
Investigated: Emerging flow cytometry applications that study participants believe offer promise in
their field. Figures and/or tables are also presented.
13.1 This chapter
13.2 Emerging applications
13.3 Discussion
14 Suppliers
Investigated: Participants current and an anticipated future (2012 – 2015) flow cytometry suppliers
or vendors, in respect of 20 specified companies, or others. Figures and/or tables are also
presented.
14.1 This chapter

8. 14.2 Current suppliers
14.3 Future suppliers
14.4 Discussion
Suppliers
Amnis (Millipore)
Apogee Flow
Applied Bioscience
BD
Beckman Coulter
BioCytex
Bio-Rad
CytonomeST
DVS Sciences
iCyt (Sony)
IntelliCyt
Life Technologies
Luminex
Miltenyi
Partec
PointCare
Stratedigm
Sysmex
TTP LabTech
Union Biometrica
Other
15 Main Flow Cytometer, Strengths and Weaknesses
Investigated: Participants main flow cytometer, in terms of their most frequently used system,
together with their strengths and weaknesses. Figures and/or tables are also presented.
15.1 This chapter
15.2 Main flow cytometer
15.3 Discussion
16 Reagents and Assays
Investigated: Participants two main suppliers of reagents and assays for use in flow cytometry.
Figures and/or tables are also presented.
16.1 This Chapter
16.2 Reagents and assays
16.3 Discussion
17 Sample Preparation
Investigated: Sample preparation methods used by participants, for flow cytometry studies.
Figures and/or tables are also presented.
10.1 This Chapter
10.2 Sample Preparation

9. 10.3 Discussion
18 Software
Investigated: Participants use of data analysis (offline) software, for flow cytometry studies.
Figures and/or tables are also presented.
18.1 This Chapter
18.2 Software
18.3 Discussion
19 Challenges
Investigated: The measurements or parameters that present the greatest technical challenge to
study participants, relating to their use of flow cytometry. The parameter, sample type (matrix) and
cytometer used were indicated, together with the main underlying reasons. Figures and/or tables
are also presented.
19.1 This chapter
19.2 Parameters
19.3 Sample type (matrix)
19.4 Flow cytometer
19.5 Reasons
19.6 Discussion
20 Innovation
Investigated: Participants views on areas of required innovation (ranked on a scale of 1 to 10,
where 1 is the least important and 10 is the most important), in respect of 10 specified areas, or
others. Figures and/or tables are also presented.
20.1 This chapter
20.2 Innovation
20.3 Discussion
Innovation Areas
Automation
Detectors
Fluidics
Lasers/Light Sources
Offline (Analysis) software
Online Data handling
Qualitative selectivity
Quantitative sensitivity
Reagents
Sample preparation
Other
21 Disease Biomarkers
Investigated: Participants two main biomarkers investigated or measured using flow cytometry and
their applications in terms of nine clinical utilities. Figures and/or tables are also presented.
21.1 This chapter
21.2 Biomarkers

10. 21.3 Clinical utility
21.4 Discussion
Clinical Utilities
Disease prognosis
Disease susceptibility or risk
Disease stage or severity
Drug discovery
Early detection of disease
Clinical trial endpoint
Guiding treatment
Response to therapy
Safety or toxicity factors
Other
22 Flow Cytometry Expenditure and Budgets
Investigated: Financial expenditure and budgets relating to the current and future use of flow
cytometry, including end-users’ current annual budgets across specified ranges (see Current
Annual financial budgets), the average flow cytometry analysis costs/sample across specified
ranges (see Flow Cytometry Costs per Sample), budget breakdown across nine specified areas
(see Budget Breakdown Areas) and overall annual financial budget for flow cytometry (either
increasing or decreasing in % terms), over the next three years (see Future Budget Changes).
Figures and/or tables are also presented.
22.1 This chapter
22.2 Annual budgets
22.3 Costs per sample
22.4 Budget breakdown
22.5 Future budget
22.6 Discussion
Current Annual Financial Budgets
<$1 k
$1 - $2.5k
$2.5 - $5k
$5 - $10k
$10 - $25k
$25 - $50k
$50 - $100k
$100 - $250k
$250 - $500k
$500k - $1 million
$1 million - $2.5 million
$2.5 million - $5 million
>$5 m

11. Flow Cytometry Costs/Sample
<$1
$1 - $2
$2 - $3
$3 - $4
$4 - $5
$5 - $7
$7 - $10
$10 - $15
$15 - $25
$25 - $40
$40 - $60
$60 - $100
$100 - $150
$150 - $200
$200 - $250
>$250
Budget breakdown Areas
Reagents and consumables
System control (data handling) software
Data analysis (offline) software
Flow cytometer instruments
Sample preparation and related instrumentation
Ancillary systems/instrumentation
General overheads
Instrument servicing/repair
Staff salaries
Other
Future budget changes
Decreasing
>-50%
-50%
-40%
-30%
-20%
-10%
-5%
0
+5%
+10%
+20%
+30%

12. +40%
+50%
>+50%
Increasing
23 Consumables
Investigated: Participants two main consumables in terms of costs, that are directly associated
with their use of flow cytometry. Figures and/or tables are also presented.
23.1 This Chapter
23.2 Consumables
23.3 Discussion
24 Quality Control
Investigated: Quality control systems or procedures adhered to in the use of flow cytometry.
Figures and/or tables are also presented.
24.1 This chapter
24.2 Quality control
24.3 Discussion
Contact: sales@reportsandreports.com for more information.